
ChromoGenics Q1 2023 - High sales activity in the quarter

Redeye provides an update on ChromoGenics following the company's Q1 2023 results. ChromoGenics continues to add strategic partners and the focus continues to be on sales activities and cost control. Sales came in lower than expected in the quarter and we expect OPEX to continue to be on the high side for longer and therefore lowers operational margins somewhat. Due to this, we adjust the valuation range to SEK0.07(0.04)–0.49 (0.043) with a base case of SEK0.10 (0.11).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

ChromoGenics Q1 2023 - High sales activity in the quarter